Vascular Smooth Muscle Cell Derived from IPS Cell of Moyamoya Disease - Comparative Characterization with Endothelial Cell Transcriptome
- PMID: 32992193
- DOI: 10.1016/j.jstrokecerebrovasdis.2020.105305
Vascular Smooth Muscle Cell Derived from IPS Cell of Moyamoya Disease - Comparative Characterization with Endothelial Cell Transcriptome
Abstract
Background: Moyamoya disease (MMD) is an occlusive cerebrovascular disease, causing stroke in children and young adults with unknown etiology. The fundamental pathology is fibrocellular intimal thickening of cerebral arteries, in which vascular smooth muscle cells (VSMCs) are observed as one of the major cell types. Although the characteristics of circulating smooth muscle progenitor cells have been previously reported, the VSMCs are poorly characterized in MMD. We aimed to characterize VSMCs in MMD using induced pluripotent stem cell (iPSC)-technology.
Methods: We differentiated VSMCs from neural crest stem cells (NCSCs) using peripheral blood mononuclear cell-derived iPSCs and compared biological and transcriptome features under naïve culture conditions between three independent healthy control (HC) subjects and three MMD patients. VSMC transcriptome profiles were also compared to those of endothelial cells (ECs) differentiated from the same iPSCs.
Results: Homogeneous spindle-shaped cells differentiated from iPSCs exhibited smooth muscle cell marker expressions, including α-smooth muscle actin (αSMA, 82.3 ± 6.7% and 81.0 ± 6.7%); calponin (91.3 ± 2.1% and 90.9 ± 1.3%); myosin heavy chain-11 (MYH11, 96.9 ± 0.7% and 97.1 ± 0.3%) without significance of differences between the two groups. Real-time PCR showed few PECAM1 and CD34 gene expressions in both groups, indicating features of differentiated VSMCs. There were no significant differences in cellular proliferation (p = 0.45), migration (p = 0.60), and contractile abilities (p = 0.96) between the two groups. Transcriptome analysis demonstrated similar gene expression profiles of VSMCs in HC subjects and MMD patients with six differentially expressed genes (DEGs); while ECs showed a distinct transcriptome profile in MMD patients with 120 DEGs. The Wnt-signaling pathway was a significant pathway in VSMCs.
Conclusions: This is the first study that established VSMCs from NCSCs using MMD patient-derived iPSCs and demonstrated similar biological function and transcriptome profile of iPSC-derived VMSCs in MMD patients and HC subjects under naïve single culture condition. Comparative transcriptome features between iPSC-derived VSMCs and ECs, displaying distinct transcriptome in the ECs, suggested that pathological traits can be driven by naïve ECs predominantly and VSMCs may require specific environmental factors in MMD, which provides novel insight into the pathophysiology of MMD. Our iPSC derived VSMC model can contribute to further investigations of diagnostic and therapeutic target of MMD in addition to the current iPSC derived EC model.
Keywords: Endothelial cells; Induced pluripotent stem cells; Moyamoya disease; Neural crest stem cells; Transcriptome; Vascular smooth muscle cells.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest None.
Similar articles
-
Smooth-muscle progenitor cells isolated from patients with moyamoya disease: novel experimental cell model.J Neurosurg. 2014 Feb;120(2):415-25. doi: 10.3171/2013.9.JNS131000. Epub 2013 Oct 25. J Neurosurg. 2014. PMID: 24160477
-
In Vitro Lineage-Specific Differentiation of Vascular Smooth Muscle Cells in Response to SMAD3 Deficiency: Implications for SMAD3-Related Thoracic Aortic Aneurysm.Arterioscler Thromb Vasc Biol. 2020 Jul;40(7):1651-1663. doi: 10.1161/ATVBAHA.120.313033. Epub 2020 May 14. Arterioscler Thromb Vasc Biol. 2020. PMID: 32404006 Free PMC article.
-
Circulating miRNome profiling in Moyamoya disease-discordant monozygotic twins and endothelial microRNA expression analysis using iPS cell line.BMC Med Genomics. 2018 Aug 29;11(1):72. doi: 10.1186/s12920-018-0385-3. BMC Med Genomics. 2018. PMID: 30157848 Free PMC article.
-
Application of Induced Pluripotent Stem Cells in Moyamoya Disease: Progress and Promises.Curr Stem Cell Res Ther. 2023;18(6):733-739. doi: 10.2174/1574888X17666220607121027. Curr Stem Cell Res Ther. 2023. PMID: 35674309 Review.
-
Differentiation and Application of Induced Pluripotent Stem Cell-Derived Vascular Smooth Muscle Cells.Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2026-2037. doi: 10.1161/ATVBAHA.117.309196. Epub 2017 Aug 31. Arterioscler Thromb Vasc Biol. 2017. PMID: 28860223 Review.
Cited by
-
Understanding genomic medicine for thoracic aortic disease through the lens of induced pluripotent stem cells.Front Cardiovasc Med. 2024 Feb 19;11:1349548. doi: 10.3389/fcvm.2024.1349548. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38440211 Free PMC article. Review.
-
RNF213 loss-of-function promotes pathological angiogenesis in moyamoya disease via the Hippo pathway.Brain. 2023 Nov 2;146(11):4674-4689. doi: 10.1093/brain/awad225. Brain. 2023. PMID: 37399508 Free PMC article.
-
Physiological and pathophysiological mechanisms of the molecular and cellular biology of angiogenesis and inflammation in moyamoya angiopathy and related vascular diseases.Front Neurol. 2023 May 16;14:661611. doi: 10.3389/fneur.2023.661611. eCollection 2023. Front Neurol. 2023. PMID: 37273690 Free PMC article. Review.
-
CircZXDC Promotes Vascular Smooth Muscle Cell Transdifferentiation via Regulating miRNA-125a-3p/ABCC6 in Moyamoya Disease.Cells. 2022 Nov 26;11(23):3792. doi: 10.3390/cells11233792. Cells. 2022. PMID: 36497052 Free PMC article.
-
Vascular smooth muscle cell dysfunction in neurodegeneration.Front Neurosci. 2022 Nov 10;16:1010164. doi: 10.3389/fnins.2022.1010164. eCollection 2022. Front Neurosci. 2022. PMID: 36440263 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
